Ipamorelin Dosage: How Much to Take, When & How

Ipamorelin Dosage: How Much to Take, When & How

Overview

Ipamorelin is a synthetic pentapeptide and growth hormone secretagogue (GHS) administered via subcutaneous or intramuscular injection. It stimulates endogenous growth hormone release through ghrelin receptor activation, making it popular in research and off-label contexts for body composition, recovery, and anti-aging applications.

The standard dosing range is 200–300 mcg per injection, administered 1–3 times daily. Unlike exogenous growth hormone, ipamorelin carries a favorable safety profile with minimal impact on cortisol or prolactin at therapeutic doses. However, it is not FDA-approved for human use and is banned in competitive athletics.

This guide covers practical dosing protocols, administration methods, cycling strategies, and cost considerations based on current clinical and pharmacological data.

Standard Dosing Protocol

Basic Dosage Range

The research-backed dosing window for ipamorelin is:

• 200–300 mcg per injection
• Frequency: 1–3 times daily
• Route: Subcutaneous injection (preferred) or intramuscular injection

This translates to a daily intake of 200–900 mcg, depending on frequency and individual response.

Timing of Administration

Ipamorelin is most effective when injected:

1. First thing in the morning on an empty stomach — capitalizes on natural GH pulsatility and fasting state sensitivity
2. Pre-workout — may enhance post-exercise recovery signaling
3. Before bed — aligns with nocturnal GH secretion patterns

If using three daily injections, space doses by at least 4–6 hours to avoid receptor desensitization.

Onset and Duration

• Onset: Growth hormone elevation begins within 5–15 minutes of injection
• Peak GH response: Occurs approximately 40 minutes post-injection (0.67 hours in human studies)
• Half-life: Approximately 2 hours, meaning pituitary GH stimulation is transient
• Practical window: Each injection supports active GH release for 2–3 hours

This short half-life is why multiple daily doses are often used—each injection creates a discrete GH pulse rather than sustained elevation.

Dosing by Goal

Because ipamorelin works through endogenous GH stimulation, dose variations are subtle. However, different goals may benefit from different frequency protocols:

Fat Loss and Body Composition

Recommended dose: 200–300 mcg, 1–2 times daily

• Timing: Morning on empty stomach and/or pre-workout
• Rationale: GH stimulation promotes lipolysis and metabolic rate elevation; morning dosing maximizes fasting state effect
• Note: Evidence for fat loss in humans is limited (Tier 2). Animal studies show mixed results, with some suggesting increased body fat through non-GH mechanisms. Use realistic expectations.

Muscle Preservation and Recovery

Recommended dose: 250–300 mcg, 2–3 times daily

• Timing: Morning, pre-workout, and/or evening
• Rationale: Higher frequency supports sustained IGF-1 signaling for protein synthesis and myofibrillar repair
• Note: No human trials demonstrate muscle growth superiority over training alone. Ipamorelin may support recovery via GH-mediated mechanisms but is not a substitute for progressive resistance training.

Anti-Aging and General Health

Recommended dose: 200–250 mcg, 1–2 times daily

• Timing: Morning on empty stomach; evening optional
• Rationale: Lower frequency reduces side effect burden while maintaining GH stimulation for tissue turnover and collagen synthesis
• Note: Evidence for anti-aging in humans is mechanistic only; no clinical trials exist.

Postoperative Ileus (Clinical Evidence)

Evidence-based dose: 0.03 mg/kg (approximately 2–3 mg for a 70–100 kg adult), IV twice daily for 1–7 days post-surgery

• This is the only human RCT-supported application, showing a 7.3-hour reduction in time to first tolerated meal
• Administered intravenously in clinical settings, not subcutaneously
• Not applicable to self-administered dosing

How to Administer

Preparation

1. Reconstitution (if purchased as lyophilized powder):

   • Use bacteriostatic water (0.9% sodium chloride with 0.9% benzyl alcohol)
   • Follow manufacturer's concentration guidelines (typically 100 mcg/mL or 200 mcg/mL)
   • Store reconstituted solution at 2–8°C (refrigerated)
   • Shelf life: 30–60 days post-reconstitution

2. Measuring the dose:

   • Use an insulin syringe (U-100) or tuberculin syringe for precise measurement
   • If using 100 mcg/mL solution, a 200 mcg dose = 0.2 mL
   • If using 200 mcg/mL solution, a 200 mcg dose = 0.1 mL
   • Double-check concentration before each injection

Injection Technique

1. Site selection:

   • Subcutaneous: abdomen, thigh, or upper arm (subcutaneous fat layers preferred)
   • Rotate injection sites to prevent lipohypertrophy (tissue thickening)
   • Maintain at least 1 inch spacing between injection sites

2. Procedure:

   • Sanitize injection site with alcohol swab
   • Pinch skin to elevate subcutaneous tissue
   • Insert needle at 45–90 degree angle, 0.5 inch deep
   • Inject slowly over 2–3 seconds
   • Withdraw needle and apply light pressure with clean gauze

3. Sterility:

   • Use a fresh needle for each injection
   • Do not share needles or solutions
   • Keep vials capped and stored away from light

Side Effects During and After Injection

• Transient flushing or warmth at injection site and face (within minutes)
• Mild headache (resolving within 30–60 minutes)
• Lightheadedness or dizziness (especially on first use)
• Increased appetite (ghrelin receptor activity)
• Water retention and mild edema at higher doses or prolonged use

These are generally self-limiting and do not require intervention.

Cycling & Timing

Standard Cycle Protocol

1. On-cycle duration: 12–16 weeks of consistent daily dosing
2. Off-cycle duration: 4–8 weeks rest period
3. Rationale: Maintains pituitary sensitivity and reduces long-term desensitization risk

Pulsatile vs. Continuous Dosing

• Pulsatile (preferred): 1–3 discrete injections per day, 4–6 hours apart — preserves natural GH pulse architecture and reduces feedback suppression
• Continuous: Not applicable; ipamorelin's 2-hour half-life prevents true continuous dosing

Stacking Considerations

Ipamorelin is often combined with:

• CJC-1295 (Growth Hormone Releasing Hormone analog) — extends GH pulse amplitude
• Sermorelin (GHRH peptide) — synergistic GH stimulation
• Tesamorelin (GHRH analog) — complementary mechanism

Dosing remains unchanged when stacking; frequency may increase to accommodate multiple peptides.

Long-Term Use Considerations

• Desensitization risk: Ipamorelin demonstrates minimal desensitization at therapeutic doses due to preserved somatostatin activity, but this is not guaranteed over years of use
• Receptor tolerance: A 4–8 week off-cycle every 12–16 weeks helps maintain sensitivity
• Safety monitoring: Long-term human safety data is limited; periodic breaks are prudent

Beginner vs. Advanced Dosing

Beginner Protocol

• Starting dose: 200 mcg once daily
• Injection timing: Morning on empty stomach
• Duration: 4 weeks to assess tolerance and response
• Frequency escalation: If well-tolerated, increase to 200 mcg twice daily (morning and evening) after 4 weeks
• Monitoring: Track appetite, energy, recovery quality, and injection site reactions

Advanced Protocol

• Dose: 250–300 mcg, 2–3 times daily
• Timing: Morning, pre-workout, and evening
• Cycling: 16 weeks on, 6–8 weeks off
• Stacking: Often combined with CJC-1295 or sermorelin at separate injection times
• Variation: May adjust frequency or dose based on goals (higher frequency for recovery, lower for maintenance)

Dose Escalation Strategy

• Week 1–4: 200 mcg once daily
• Week 5–8: 200 mcg twice daily (morning + evening)
• Week 9+: 200–300 mcg two to three times daily, depending on response and goals

Do not exceed 300 mcg per single injection or 900 mcg daily without medical supervision.

Common Dosing Mistakes

1. Exceeding 300 mcg per injection

   • Increases side effect burden (water retention, appetite stimulation) without proportional GH benefit
   • May accelerate receptor desensitization

2. Injecting too frequently without spacing

   • Doses less than 4 hours apart may blunt pituitary response
   • Maintains elevated somatostatin, reducing GH secretion quality

3. Empty stomach requirement ignored

   • Eating within 30–60 minutes of injection reduces GH stimulation efficiency
   • Protein and carbohydrates blunt GH response most significantly

4. Inconsistent injection timing

   • Ipamorelin relies on pulsatile dosing; erratic timing undermines effectiveness
   • Set alarm reminders if using multiple daily doses

5. Injecting into the same site repeatedly

   • Creates lipohypertrophy and may reduce absorption variability
   • Rotate sites systematically (abdomen day 1, thigh day 2, arm day 3, repeat)

6. Mixing with food or taking oral medications concurrently

   • Peptides are destroyed by gastric acid; only injection is effective
   • Space ipamorelin injections 2+ hours from oral medications when possible

7. Skipping the off-cycle

   • Continuous use without breaks increases desensitization risk
   • Follow a structured 12–16 weeks on, 4–8 weeks off approach

8. Inadequate storage

   • Reconstituted solutions degrade at room temperature
   • Keep vials refrigerated (2–8°C) at all times

Cost Considerations

• Typical monthly cost: $40–$120
• Price per injection (at standard 200 mcg dose):
  • Once daily: ~$1.50–$4.00 per injection
  • Twice daily: ~$3.00–$8.00 daily
  • Three times daily: ~$4.50–$12.00 daily

Costs vary based on vendor, purity, concentration, and bulk purchasing. Higher-quality pharmaceutical-grade preparations typically cost toward the upper end of this range.

Dosage Summary Table

Disclaimer

This dosage guide is for educational purposes only and does not constitute medical advice. Ipamorelin is not FDA-approved for human use and carries unknown long-term safety risks. Individuals considering ipamorelin should consult a qualified healthcare provider before use, particularly those with active malignancies, diabetic retinopathy, carpal tunnel syndrome, or other chronic conditions. This guide is based on research data and does not endorse off-label use. Users assume full responsibility for their health decisions.